A Study of IMC-1 In Patients With Fibromyalgia

A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

Inclusion Criteria:

• Diagnosis of fibromyalgia
• English speaker

Exclusion Criteria:

• Rheumatologic diseases
• Bipolar disease, OCD, severe anxiety, schizophrenia
• Systemic infection, severe cardiac disease, chronic steroid usage
• chronic opioid usage